The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.
Medscape Medical News
The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.
Medscape Medical News